C4 Therapeutics, Inc. Announces Positive Data from CFT7455 P

C4 Therapeutics, Inc. presented clinical data from the ongoing Phase 1 dose escalation portion of its Phase 1/2 clinical trial of CFT7455, a MonoDAC?? degrader of IKZF1/3, for the potential treatment...

Related Keywords

, International Myeloma Working Group , Therapeutics Inc , Stable Disease , Partial Response , Stringent Complete Response , Very Good Partial Response , Complete Phase , Markets ,